Wave Life Sciences (WVE) Q2 FY26 earnings call

Wave Life Sciences advanced its lead RNAi and RNA editing programs, WVE-007 for obesity and WVE-006 for AATD, into their next development stages, leveraging proprietary chemistry and human genetic insights. The company is actively pursuing an accelerated approval pathway for WVE-006 and initiating combination and maintenance studies for WVE-007, while maintaining a strong cash position. The strategy includes exploring partnerships for DMD programs amidst a changing landscape.